Education
About Us
Working with TipRanks
Follow Us
PolyPeptide Group AG (CH:PPGN)
:PPGN
PPGN Stock Chart & Stats
CHF25.25
CHF1.30(6.77%)
At close: 4:00 PM EST
CHF25.25
CHF1.30(6.77%)
Day’s Range― - ―
52-Week RangeCHF13.22 - CHF30.25
Previous CloseN/A
Volume22.87K
Average Volume (3M)34.07K
Market Cap
CHF834.04M
Enterprise ValueCHF686.97M
Total Cash (Recent Filing)CHF76.69M
Total Debt (Recent Filing)CHF100.45M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 12, 2026EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding33,125,000
10 Day Avg. Volume33,840
30 Day Avg. Volume34,067
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)2.78
Price to Sales (P/S)2.94
P/FCF Ratio409.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PolyPeptide Group AG News
PPGN FAQ
What was PolyPeptide Group AG’s price range in the past 12 months?
PolyPeptide Group AG lowest stock price was CHF13.22 and its highest was CHF30.25 in the past 12 months.
What is PolyPeptide Group AG’s market cap?
PolyPeptide Group AG’s market cap is CHF834.04M.
When is PolyPeptide Group AG’s upcoming earnings report date?
PolyPeptide Group AG’s upcoming earnings report date is Mar 12, 2026 which is in 74 days.
How were PolyPeptide Group AG’s earnings last quarter?
PolyPeptide Group AG released its earnings results on Aug 12, 2025. The company reported -CHF0.748 earnings per share for the quarter, missing the consensus estimate of -CHF0.533 by -CHF0.215.
Is PolyPeptide Group AG overvalued?
According to Wall Street analysts PolyPeptide Group AG’s price is currently Overvalued.
Does PolyPeptide Group AG pay dividends?
PolyPeptide Group AG pays a Notavailable dividend of CHF0.3 which represents an annual dividend yield of N/A. See more information on PolyPeptide Group AG dividends here
What is PolyPeptide Group AG’s EPS estimate?
PolyPeptide Group AG’s EPS estimate is 0.27.
How many shares outstanding does PolyPeptide Group AG have?
PolyPeptide Group AG has 33,125,000 shares outstanding.
What happened to PolyPeptide Group AG’s price movement after its last earnings report?
PolyPeptide Group AG reported an EPS of -CHF0.748 in its last earnings report, missing expectations of -CHF0.533. Following the earnings report the stock price went up 9.255%.
Which hedge fund is a major shareholder of PolyPeptide Group AG?
Currently, no hedge funds are holding shares in CH:PPGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PolyPeptide Group AG
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Galderma Group AG
―
Options Prices
Currently, No data available
---